Pharmacogenomic test costsaving in depression and anxiety

Pharmacogenomic test costsaving in depression and anxiety PharmacoEconomics & Outcomes News 792, p24 - 2 Dec 2017 Pharmacogenomic test cost saving in depression and anxiety The use of a pharmacogenomic test (IDgenetix) to guide treatment appears to be cost effective in patients with major depressive disorder with or without anxiety, according to findings of an AltheaDx-affiliated study published in PharmacoEconomics. A discrete-event simulation model populated with clinical trial data was used to evaluate the cost effectiveness of IDgenetix-guided treatment compared with treatment as usual in patients with moderate or severe major depressive disorder and/or anxiety, from a US societal perspective over a three-year time horizon. The assumed cost of the IDgenetix test was $2000. The predicted cumulative remission rate was 78% with the IDgenetix strategy versus 66% with usual care, and the estimated QALY gain was 2.09 and 1.94 per patient, respectively. Estimated total costs were $14 124 and $14 659, respectively, resulting in cost savings of $535 per patient in the IDgenetix group. Use of the IDgenetix test was therefore dominant (more effective and less costly) compared with usual care. QALY gains and cost savings were greater in patients with depression with or without comorbid anxiety than in those with anxiety only. Moreover the incremental QALY gain with IDgenetix was higher in patients with severe depression (+0.49) and cost savings were greater ( $6871 per patient). Sensitivity analysis showed that estimated cost savings with the IDgenetix strategy were $6000 over a 10-year time horizon and more than $10 000 over a lifetime time horizon. test on treatment "The impact of the IDgenetix efficacy is larger or, at minimum, comparable to what one might expect from a novel and effective therapeutic option," said the authors. "Overall, several features of the IDgenetix test, such as the efficacy of a guided treatment strategy, one-time test cost, and the prospect of using test results for guiding future episodes of depression or anxiety, make it a potentially dominant strategy compared with usual care," they added. * 2017 US dollars Najafzadeh M, et al. Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix(R)) to Guide Treatment of Patients with Depression and/or Anxiety. PharmacoEconomics : 6 Nov 2017. Available from: URL: http://doi.org/10.1007/s40273-017-0587-0 803283872 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Pharmacogenomic test costsaving in depression and anxiety

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/pharmacogenomic-test-costsaving-in-depression-and-anxiety-9mIxpgP6TM
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4547-x
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p24 - 2 Dec 2017 Pharmacogenomic test cost saving in depression and anxiety The use of a pharmacogenomic test (IDgenetix) to guide treatment appears to be cost effective in patients with major depressive disorder with or without anxiety, according to findings of an AltheaDx-affiliated study published in PharmacoEconomics. A discrete-event simulation model populated with clinical trial data was used to evaluate the cost effectiveness of IDgenetix-guided treatment compared with treatment as usual in patients with moderate or severe major depressive disorder and/or anxiety, from a US societal perspective over a three-year time horizon. The assumed cost of the IDgenetix test was $2000. The predicted cumulative remission rate was 78% with the IDgenetix strategy versus 66% with usual care, and the estimated QALY gain was 2.09 and 1.94 per patient, respectively. Estimated total costs were $14 124 and $14 659, respectively, resulting in cost savings of $535 per patient in the IDgenetix group. Use of the IDgenetix test was therefore dominant (more effective and less costly) compared with usual care. QALY gains and cost savings were greater in patients with depression with or without comorbid anxiety than in those with anxiety only. Moreover the incremental QALY gain with IDgenetix was higher in patients with severe depression (+0.49) and cost savings were greater ( $6871 per patient). Sensitivity analysis showed that estimated cost savings with the IDgenetix strategy were $6000 over a 10-year time horizon and more than $10 000 over a lifetime time horizon. test on treatment "The impact of the IDgenetix efficacy is larger or, at minimum, comparable to what one might expect from a novel and effective therapeutic option," said the authors. "Overall, several features of the IDgenetix test, such as the efficacy of a guided treatment strategy, one-time test cost, and the prospect of using test results for guiding future episodes of depression or anxiety, make it a potentially dominant strategy compared with usual care," they added. * 2017 US dollars Najafzadeh M, et al. Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix(R)) to Guide Treatment of Patients with Depression and/or Anxiety. PharmacoEconomics : 6 Nov 2017. Available from: URL: http://doi.org/10.1007/s40273-017-0587-0 803283872 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off